NEW ORLEANS--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
An artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people ages 2 to 72 with type 1 diabetes, according to a new combined ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
A new study evaluated the effect of hybrid-closed loop Control-IQ technology in the pooled data from three randomized controlled trials, comparing Control-IQ to a control group using continuous ...
A new study reveals that an artificial pancreas developed at UVA improves blood sugar control for children ages 2 to 6 who have Type 1 diabetes. Participants of the study spent three more hours per ...
Please provide your email address to receive an email when new articles are posted on . Managing glucose levels during pregnancy in women with type 1 diabetes is important for the mother and child.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback